Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water

第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果

基本信息

  • 批准号:
    10458235
  • 负责人:
  • 金额:
    $ 104.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2026-09-16
  • 项目状态:
    未结题

项目摘要

Dental health benefits of fluoride in drinking water have never been tested in a randomized controlled trial (RCT). Instead, results from observational studies and a few non-randomized, community intervention studies were sufficient to justify addition of fluoride to many public water systems during the 20th century and to defend against fluoridation’s critics. However, growth in fluoridated public water systems has stalled, leaving 100 million Americans living in places that do not have fluoridated water and which probably never will. A related problem is that, nationwide, 15% of children do not drink tap water for reasons ranging from consumer preference to distrust of public water. One solution, capitalizing on consumers’ demand for bottled water, is to increase consumption of fluoridated bottled water. However, RCT evidence of dental health benefits of fluoridated bottled water will be essential if public health is to embrace it as a strategy to extend fluoridation. In the absence of a precedent, and in the face of uncertainty as to compliance and likely effect size of the intervention, a fully powered RCT is premature. We instead propose a phase II, proof-of-concept RCT to evaluate dental caries preventive effects of fluoridated bottled water in a community not served by water fluoridation. The primary recruitment population is ~470 babies born during a one-year period in Kinston, NC, the state’s community with the largest non-fluoridated public water system where caries prevalence exceeds the state average. In households where measured content of fluoride in tap water is <0.2 ppm, we will randomize 200 infant/family dyads in a 1:1 ratio to receive either fluoridated or non-fluoridated bottled water. The two types of commercially water in 5-gallon bottles will be relabeled to mask infants, families and researchers as to the fluoride content. For 3½ years after randomization, each household will be provided with water, dispensers and other supplies to encourage water consumption consistent with nutritional recommendations. Bottled water consumption will be monitored and fingernail clippings collected to provide a biomarker-measure of fluoride intake. A dental examination conducted when children are aged 48?3 months will measure caries experience using the index of decayed, missing and filled tooth surfaces (dmfs). Statistical analysis will compare mean dmfs between study-groups to generate effect size estimates and standard errors needed to calculate sample size requirement for a future, multi-site, Phase III RCT. The investigative team has a strong record of accomplishment in observational and interventional studies of dental caries in children, and is experienced in work needed to plan (during the UG3 phase) and conduct (during the 5-year UH3 phase) the study as required by PAR-18-547. Local, state and national stakeholders have expressed support for the proposed study, noting its potential to improve oral health in underserved communities. By applying the rigor of a placebo-controlled RCT design, the study will address a serious shortfall in the evidence that hampers the nation’s primary public health strategy for dental caries prevention.
饮用水中氟化物对牙齿健康的益处从未在随机对照试验中进行过测试

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gary Douglas Slade其他文献

Gary Douglas Slade的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gary Douglas Slade', 18)}}的其他基金

Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water
第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果
  • 批准号:
    10472070
  • 财政年份:
    2021
  • 资助金额:
    $ 104.92万
  • 项目类别:
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease
牙周病是否与非酒精性脂肪肝的病因有关
  • 批准号:
    9111407
  • 财政年份:
    2016
  • 资助金额:
    $ 104.92万
  • 项目类别:
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease
牙周病是否与非酒精性脂肪肝的病因有关
  • 批准号:
    9233074
  • 财政年份:
    2016
  • 资助金额:
    $ 104.92万
  • 项目类别:
Effects of cumulative stress and change in pain regulation on risk of chronic TMD
累积压力和疼痛调节变化对慢性 TMD 风险的影响
  • 批准号:
    8440291
  • 财政年份:
    2012
  • 资助金额:
    $ 104.92万
  • 项目类别:
Effects of cumulative stress and change in pain regulation on risk of chronic TMD
累积压力和疼痛调节变化对慢性 TMD 风险的影响
  • 批准号:
    8282086
  • 财政年份:
    2012
  • 资助金额:
    $ 104.92万
  • 项目类别:
Planning for International Studies of Population Oral Health Determinants
人口口腔健康决定因素的国际研究规划
  • 批准号:
    7449834
  • 财政年份:
    2008
  • 资助金额:
    $ 104.92万
  • 项目类别:
Planning for International Studies of Population Oral Health Determinants
人口口腔健康决定因素的国际研究规划
  • 批准号:
    7643354
  • 财政年份:
    2008
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8457069
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8274677
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8425167
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:

相似国自然基金

药用植物华泽兰中改善II型糖尿病并发抑郁症活性先导化合物的挖掘及其作用机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
脂肪干细胞外泌体调节Bax/BAK1-caspase-3/caspase8信号轴影响II型肺泡上皮细胞衰老在脓毒症肺损伤中的作用及机制
  • 批准号:
    MS25H010004
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
1 类新药研发后补助(治疗用生物制品 1 类 MG-K10 人源化单抗注射液、II 期临床试验)
  • 批准号:
    2025JK2095
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
1 类新药研发后补助(治疗用生物制品 1 类MG-ZG122 人源化单抗注射液、II 期临床试验)
  • 批准号:
    2025JK2097
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
黏土矿物结构Fe(II)跨界面驱动氧化铁结合态有机质释放和转化机制
  • 批准号:
    2025JJ50205
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
NIR-II荧光内镜辅助胰腺癌术中肿瘤活性评估的可视化研究
  • 批准号:
    2025JJ50653
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
整合素β5调控TGFβ II型受体细胞内转 运促进胃癌转移的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
有序组装型NIR-II荧光探针的构建及疾病辅助诊断应用
  • 批准号:
    2025JJ40014
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
αvβ3整合素靶向有机探针用于NIR-II FL/MRI双模态成像引导的三阴性乳腺癌光热治疗研究
  • 批准号:
    2025JJ81013
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
全钒液流电池负极V(II)/V(III)电化学氧化还原的催化机理研究
  • 批准号:
    2025JJ50094
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water
第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果
  • 批准号:
    10472070
  • 财政年份:
    2021
  • 资助金额:
    $ 104.92万
  • 项目类别:
FMitF: Track II: Strengthening the integration of the CVC4 SMT solver in the Coq proof assistant
FMITF:轨道 II:加强 Coq 证明助手中 CVC4 SMT 求解器的集成
  • 批准号:
    2019348
  • 财政年份:
    2020
  • 资助金额:
    $ 104.92万
  • 项目类别:
    Standard Grant
Clinical and Microbiological Studies of Faecal Microbiota Transplantation in Ulcerative Colitis - A Phase II, Multicentre, Randomised Double Blind, Exploratory Proof of Concept, Placebo Controlled Trial
粪便微生物群移植治疗溃疡性结肠炎的临床和微生物学研究 - II 期、多中心、随机双盲、探索性概念验证、安慰剂对照试验
  • 批准号:
    nhmrc : 1055871
  • 财政年份:
    2013
  • 资助金额:
    $ 104.92万
  • 项目类别:
    Postgraduate Scholarships
SBIR Phase II: A new drug discovery method to transform peptides to small molecules: proof of principle with p53-hdm2
SBIR II 期:一种将肽转化为小分子的新药物发现方法:用 p53-hdm2 进行原理证明
  • 批准号:
    1127154
  • 财政年份:
    2011
  • 资助金额:
    $ 104.92万
  • 项目类别:
    Standard Grant
A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refracto
研究复发/难治患者激酶抑制作用的 II 期概念验证试验
  • 批准号:
    8110864
  • 财政年份:
    2011
  • 资助金额:
    $ 104.92万
  • 项目类别:
A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refracto
研究复发/难治患者激酶抑制作用的 II 期概念验证试验
  • 批准号:
    8234975
  • 财政年份:
    2011
  • 资助金额:
    $ 104.92万
  • 项目类别:
Proof-based Research on the Change of Japanese Communication Behavior after World War II
二战后日本传播行为变化的实证研究
  • 批准号:
    19520405
  • 财政年份:
    2007
  • 资助金额:
    $ 104.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PH I/II PROOF OF CONCEPT TRIAL OF ANTHRAX VACCINE COMBINED WITH CPG 7909
炭疽疫苗与 CPG 7909 结合的 PH I/II 概念验证试验
  • 批准号:
    7378165
  • 财政年份:
    2006
  • 资助金额:
    $ 104.92万
  • 项目类别:
PH I/II PROOF OF CONCEPT TRIAL OF ANTHRAX VACCINE COMBINED WITH CPG 7909
炭疽疫苗与 CPG 7909 结合的 PH I/II 概念验证试验
  • 批准号:
    7204773
  • 财政年份:
    2005
  • 资助金额:
    $ 104.92万
  • 项目类别:
Differentiation of embryonic stem cells into type II alveolar epithelial cells: Identification of key factors for differentiation, proof of functionality and establishment of a preclinical nonhuman primate in vitro model
胚胎干细胞向II型肺泡上皮细胞的分化:分化关键因素的鉴定、功能性证明以及临床前非人灵长类动物体外模型的建立
  • 批准号:
    5419107
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:
    Clinical Research Units
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了